Recombinant Human KIR3DL2/CD158k Fc Chimera Protein, CF
| Name | Recombinant Human KIR3DL2/CD158k Fc Chimera Protein, CF |
|---|---|
| Supplier | R&D Systems |
| Catalog | 2878-KR |
| Category | Protein |
| Prices | $329.00 |
| Sizes | 50 µg |
| Species Reactivities | Human |
| Nature | Recombinant |
| Source | Mouse myeloma cell line, NS0-derived Human KIR3DL2 (Leu22-Leu339) Accession # P43630 IEGRMD Human IgG 1 (Pro100-Lys330) N-terminus C-terminus |
| Purity | >90%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
| Bioactivity | Measured by its ability to bind HLA on MDA‑MB‑231 human breast cancer cells. The ED 50 for this effect is 0.06-0.36 μg/mL. |
| Endotoxin | <1.0 EU per 1 μg of the protein by the LAL method. |
| SwissProt/Accession | P43630 |
| Gene | KIR3DL2 |
| Sequence | Leu22 |
| Supplier Page | Shop |
Product images
Recombinant Human KIR3DL2/CD158k Fc Chimera (Catalog # 2878-KR)binds to MDA-MB-231 human breast cancer cells. The ED 50 for this effect is0.06-0.36 μg/mL.